StockNews.com Initiates Coverage on Milestone Scientific (NYSE:MLSS)

Analysts at StockNews.com assumed coverage on shares of Milestone Scientific (NYSE:MLSS) in a research report issued on Sunday. The firm set a “hold” rating on the stock.

Separately, Benchmark began coverage on Milestone Scientific in a research note on Thursday, October 10th. They issued a “speculative buy” rating and a $1.25 price target on the stock.

Milestone Scientific Stock Down 8.9 %

Shares of NYSE:MLSS opened at $0.69 on Friday. The firm has a market cap of $53.32 million, a P/E ratio of -10.83 and a beta of 1.08. The company’s 50-day moving average price is $0.89 and its two-hundred day moving average price is $0.83. Milestone Scientific has a 12 month low of $0.52 and a 12 month high of $1.10.

Milestone Scientific (NYSE:MLSS) last announced its quarterly earnings data on Thursday, August 15th. The company reported ($0.02) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.01). Milestone Scientific had a negative net margin of 54.87% and a negative return on equity of 60.78%. The company had revenue of $1.85 million during the quarter.

Insider Buying and Selling at Milestone Scientific

In related news, Director Leonard Osser sold 107,984 shares of the business’s stock in a transaction that occurred on Tuesday, October 22nd. The shares were sold at an average price of $0.93, for a total transaction of $100,425.12. Following the completion of the transaction, the director now owns 4,606,882 shares in the company, valued at approximately $4,284,400.26. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 251,106 shares of company stock worth $236,451 over the last three months. Company insiders own 24.75% of the company’s stock.

Milestone Scientific Company Profile

Milestone Scientific Inc, a biomedical technology research and development company, patents, designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates through Dental and Medical segments.